TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19177420

Group type: EXPERIMENTAL
Intervention: Recurrent laryngeal nerve (RLN) monitoring
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard protection (visualization)
Number of subjects: 1000
Study: 17679566

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15551388

Group type: EXPERIMENTAL
Intervention: Valerian 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Valerian 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11431240

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine, 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol, 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 0
Study: 9725662

Group type: EXPERIMENTAL
Intervention: 1‐monoglyceride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: triglyceride
Number of subjects: 12
Study: 7884790

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg to 15 mg once daily or 2.5 mg to 10 mg twice daily)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Isradipine with concomitant HCTZ (12.5 mg to 50 mg once daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (HCTZ)
Number of subjects: 136
Study: 3287901

Group type: EXPERIMENTAL
Intervention: Diazemuls
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Consultant endoscopist
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Inexperienced resident
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Experienced resident
Number of subjects: 120
Study: 30268189

Group type: EXPERIMENTAL
Intervention: Group O (surgical method O)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Group L (surgical method L)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group O
Number of subjects: 70

Group type: COMPARATOR
Intervention: Group L
Number of subjects: 70
Study: 27919638

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Atorvastatin 80mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo + Atorvastatin 80mg
Number of subjects: 87
Study: 26240491

Group type: EXPERIMENTAL
Intervention: Switching from cow's milk feeding to special formula or breast feeding in the infant group (n=8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Restriction of suspected foods and/or administration of ketotifen in the pEGE group (n=9)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Restriction of suspected foods in both hEGE and pEGE groups
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison between infant group and child group
Number of subjects: 22
Study: 23979954

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change (ILS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20351570

Group type: EXPERIMENTAL
Intervention: 1-Hz right prefrontal rTMS
Number of subjects: 60

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 60
Study: 17882913

Group type: EXPERIMENTAL
Intervention: 10 mg of cetirizine once per day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast once per day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 mg of cafirlukast twice per day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of 20 mg of zafirlukast and 10 mg of cetirizine once per day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of 20 mg of zafirlukast twice per day and 10 mg cetirizine once per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-dose anti-LT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antihistamine alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anti-LT treated groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose anti-LT or combination of low-dose anti-LT and antihistamine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anti-LT
Number of subjects: 120
Study: 15215154

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular corticosteroids (triamcinolone)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11577957

Group type: EXPERIMENTAL
Intervention: SRP + TCF (local tetracycline fiber in pockets with PD > or =5 mm)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP + AUG (amoxicillin/clavulanic acid 500 mg tid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP + TCF (local tetracycline fiber)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP + AUG (amoxicillin/clavulanic acid)
Number of subjects: 30
Study: 9835240

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 7927581

Group type: EXPERIMENTAL
Intervention: Phototherapy with TcBI estimation on the forehead (uncovered group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phototherapy with TcBI estimation on the forehead (covered group)
Number of subjects: 100
Study: 2600826

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (2 or 4 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tobacco abstinence (no nicotine for 10 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (4 mg)
Number of subjects: 15
Study: 45483

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Thiazinamium
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study: 29481425

Group type: EXPERIMENTAL
Intervention: 20% human albumin and crystalloids
Number of subjects: 958

Group type: COMPARATOR
Intervention: Crystalloid solutions alone
Number of subjects: 958
Study: 28284926

Group type: EXPERIMENTAL
Intervention: Dextrose infusion (0.9% saline control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acetylcholine infusion (both arms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dextrose infusion (after reperfusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 26330582

Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metal-on-metal total hip arthroplasty (MoM THA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene total hip arthroplasty (CoP THA)
Number of subjects: 36
Study: 24495641

Group type: EXPERIMENTAL
Intervention: Inhalation of a mixture of 65% nitrous oxide and oxygen during dressing change
Number of subjects: 240

Group type: COMPARATOR
Intervention: Inhalation of oxygen during dressing change
Number of subjects: 240
Study: 21626011

Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 8 mg/mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 5 mg/mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lidocaine concentration of 3.3 mg/mL
Number of subjects: 102
Study: 18636531

Group type: EXPERIMENTAL
Intervention: Virtual Patient Examinations (VPEs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no supplemental CE instruction)
Number of subjects: 82
Study: 16515571

Group type: EXPERIMENTAL
Intervention: Epidoxorubicin 120 mg/sqm for 4 months
Number of subjects: 138

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 138
Study: 15184237

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy modified for adolescents (IPT-A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study: 11434168

Group type: EXPERIMENTAL
Intervention: Children with chronic glomerulonephritis (GN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Children with GN and syndrome nephroticum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (15 healthy children)
Number of subjects: 60
Study: 9481146

Group type: EXPERIMENTAL
Intervention: EuroQoL questionnaire
Number of subjects: 214
Study: 8021765

Group type: EXPERIMENTAL
Intervention: Zidovudine (60 to 180 mg/m2 per dose) given orally every 6 hours
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Didanosine (60 to 180 mg/m2 per dose) given every 12 hours
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of zidovudine and didanosine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine after 4 and 12 weeks of treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 54
Study: 2723711

Group type: EXPERIMENTAL
Intervention: Alarm algorithm for ventilator monitoring
Number of subjects: 2
Study: 810269

Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate (SCG), administered as a fine spray six times a day for 4 weeks, approximately 31-32 mg daily.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo solution, administered as a fine spray six times a day for 4 weeks.
Number of subjects: 0
Study: 30107621

Group type: EXPERIMENTAL
Intervention: Game decision aid
Number of subjects: 73

Group type: COMPARATOR
Intervention: Brochure (Control)
Number of subjects: 73
Study: 29232379

Group type: COMPARATOR
Intervention: sufentanil 0.1 μg/kg (group S)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg/kg (group N1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.15 mg/kg (group N2)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.2 mg/kg (group N3)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: nalbuphine groups (N1, N2, N3)
Number of subjects: 240
Study: 26225794

Group type: EXPERIMENTAL
Intervention: 5α-reductase inhibitors (5αRIs) for 3 years after TURP
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 23072267

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus aromatherapy (rose essential oil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy plus placebo (physiological serum, 0.9% NaCl)
Number of subjects: 80
Study: 21663811

Group type: EXPERIMENTAL
Intervention: Airtraq (A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: GlideScope (G)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Macintosh (M)
Number of subjects: 62
Study: 19801025

Group type: EXPERIMENTAL
Intervention: Bolus plus bivalirudin infusion during and after PCI (4 hours, n = 88)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Bolus plus bivalirudin infusion during PCI (n = 90)
Number of subjects: 178
Study: 16788335

Group type: EXPERIMENTAL
Intervention: Early access to physical therapy treatment within 2 days (n=32)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with a 4-week waiting list (n=28)
Number of subjects: 60
Study: 15660594

Group type: EXPERIMENTAL
Intervention: Stretch-release relaxation training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cognitive relaxation training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (test control)
Number of subjects: 65
Study: 10875212

Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 9594558

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endothelin-1,2 (ET-1,2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y (NPY)
Number of subjects: 27
Study: 8322577

Group type: EXPERIMENTAL
Intervention: Low-viscosity cement
Number of subjects: 267

Group type: COMPARATOR
Intervention: High-viscosity cement
Number of subjects: 267
Study: 3793001

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg i.v.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg i.v.)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31599603

Group type: EXPERIMENTAL
Intervention: CM-reinforced exercise intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CM for completing exercise goals
Number of subjects: 120

Group type: COMPARATOR
Intervention: CM for completing general nonexercise goals
Number of subjects: 120
Study: 31151228

Group type: EXPERIMENTAL
Intervention: early time-restricted feeding (eTRF)
Number of subjects: 11
Study: 28952284

Group type: EXPERIMENTAL
Intervention: Role playing
Number of subjects: 314

Group type: COMPARATOR
Intervention: Lecture (Control)
Number of subjects: 314
Study: 26923352

Group type: EXPERIMENTAL
Intervention: Steroid-sparing immunosuppressive regimens
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: JCPyV positive donor IgG antibodies
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: JCPyV positive
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Negative JCPyV donor
Number of subjects: 112
Study: 24433609

Group type: EXPERIMENTAL
Intervention: Motivational interviewing based intervention (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (n=15)
Number of subjects: 30
Study: 21414035

Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 6 months
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months and 6 months
Number of subjects: 418
Study: 19996425

Group type: EXPERIMENTAL
Intervention: artesunate‐mefloquine (AMQ)
Number of subjects: 342

Group type: COMPARATOR
Intervention: mefloquine (MQ)
Number of subjects: 342
Study: 17451613

Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (GI) breakfast
Number of subjects: 2

Group type: COMPARATOR
Intervention: High-glycaemic-index (GI) breakfast
Number of subjects: 2
Study: 15105027

Group type: EXPERIMENTAL
Intervention: High-protein liquid nutritional supplement (Boost HP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard liquid nutritional supplement (Ensure)
Number of subjects: 46
Study: 11253315

Group type: EXPERIMENTAL
Intervention: Bimanual in‐phase and antiphase tapping, clapping, galloping, galloping while clapping, crawling
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Natural limb frequencies
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Single limb timing consistency
Number of subjects: 15
Study: 9589230

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for 2 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sunflower oil (6 g daily for 2 months)
Number of subjects: 12
Study: 7990660

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 35

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 35
Study: 2660451

Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UDCG 115 BS (chronic treatment: 2 x 5 or 2 x 10 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30329038

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maribavir 800 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maribavir 1200 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maribavir (all doses combined)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 120
Study: 28474460

Group type: EXPERIMENTAL
Intervention: OXN PR (oxycodone-naloxone prolonged-release) at a mean daily dose of 130.7 mg (range 120-180 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OXN PR (oxycodone-naloxone prolonged-release)
Number of subjects: 0
Study: 26342136

Group type: EXPERIMENTAL
Intervention: Intervention program (12 sessions over 6 months)
Number of subjects: 36
Study: 24077372

Group type: EXPERIMENTAL
Intervention: Strength training group (19 boys, 22 girls)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Endurance training group (21 boys, 24 girls)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (18 boys, 21 girls)
Number of subjects: 125
Study: 21231888

Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with high-viscosity hydroxypropylmethyl cellulose (HPMC-K4M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with sodium carboxymethyl cellulose (NaCMC) and HPMC-E5LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline buccoadhesive tablets with HPMC-E5LV
Number of subjects: 0
Study: 19728577

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment (fixed appliance treatment)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Class II group (untreated)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Normal group (normal occlusion)
Number of subjects: 183
Study: 17760537

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler with carbon tips (VS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler with plastic tips (PS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ultrasonic scaler with metallic tips (ES)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers (VS, PS, ES)
Number of subjects: 14
Study: 15050696

Group type: EXPERIMENTAL
Intervention: IL‐1alpha (-889C/T) polymorphism in PD patients
Number of subjects: 176

Group type: COMPARATOR
Intervention: IL‐1alpha (-889C/T) polymorphism in control individuals
Number of subjects: 176
Study: 15061246

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 0
Study: 10933062

Group type: EXPERIMENTAL
Intervention: Tirapazamine (TPZ) administration
Number of subjects: 13
Study: 8569225

Group type: EXPERIMENTAL
Intervention: Ketanserin for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin between 8 and 12 weeks of rHuEpo therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups of patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin administration
Number of subjects: 0
Study: 2037667

Group type: EXPERIMENTAL
Intervention: Intranasal bivalent live attenuated influenza vaccine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Parenteral trivalent inactivated subvirion vaccine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 6909025

Group type: EXPERIMENTAL
Intervention: Timolol 5 mg/day + 1% adrenaline eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol 20 mg/day + 1% adrenaline eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 5 mg/day + placebo eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 20 mg/day + placebo eye drops
Number of subjects: 0
Study: 31571150

Group type: EXPERIMENTAL
Intervention: Halibut maki roll with newly harvested Greenlandic seaweed salad
Number of subjects: 9

Group type: COMPARATOR
Intervention: Halibut maki roll with no seaweed salad
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Halibut maki roll with Japanese seaweed salad
Number of subjects: 9
Study: 31530354

Group type: COMPARATOR
Intervention: 2006 WHO growth standard (W-group)
Number of subjects: 15019

Group type: EXPERIMENTAL
Intervention: 2005 Shanghai growth standard (S-group)
Number of subjects: 15019
Study: 29463288

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine treatment administered through the local health system.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract).
Number of subjects: 0
Study: 26739816

Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous moderate intensity exercise (CONT)
Number of subjects: 12
Study: 24953218

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5% racemic bupivacaine
Number of subjects: 20
Study: 22451450

Group type: EXPERIMENTAL
Intervention: Azosemide
Number of subjects: 320

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 320
Study: 20399288

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 24 months
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 18083404

Group type: EXPERIMENTAL
Intervention: Chemotherapy with fluorouracil and folinic acid (n=1622)
Number of subjects: 3239

Group type: COMPARATOR
Intervention: Observation (n=1617)
Number of subjects: 3239
Study: 16139122

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose before PCI and 75 mg daily for one year afterward
Number of subjects: 2116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2116

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2116
Study: 12153125

Group type: EXPERIMENTAL
Intervention: Smiling in photographs
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Relative social status
Number of subjects: 496
Study: 10456461

Group type: EXPERIMENTAL
Intervention: Plasmin-alpha2-antiplasmin complex (PAP) levels in patients with AF
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: High-risk patients classified by risk stratification criteria
Number of subjects: 586

Group type: COMPARATOR
Intervention: PAP levels in patients receiving warfarin
Number of subjects: 586
Study: 8526244

Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31687396

Group type: EXPERIMENTAL
Intervention: Lycopene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pyrene
Number of subjects: 0
Study: 27791253

Group type: EXPERIMENTAL
Intervention: HPG/PG/PL
Number of subjects: 210

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 210